Sorbonne University, born of the merger between Paris-Sorbonne and Pierre and Marie Curie universities, is a world-class multidisciplinary intensive research university. Sorbonne University covers the entire disciplinary event of literature, medicine and science.

‍

Since 2015, Professor Francis Berenbaum, deputy director of the Saint Antoine research center (Sorbonne University - INSERM) has been working in close collaboration with the teams of 4P-Pharma and SATT Lutech, on the 4P004 project, now developed by 4Moving Biotech .

Founded in 1636, Utrecht University is one of the largest research universities of Europe, with over thirty thousand students and a staff of more than six thousand. Dedicated to performing groundbreaking research aimed at resolving large global issues, their culture of cooperation is a breeding ground for innovation, new insights, and social impact.

‍

Marianna Tryfonidou’s team from Utrecht University, is part of our European Consortium with 4Moving Biotech, Chondrometrics and AO Research Institute Davos which has been awarded funding through the highly competitive EUREKA-Eurostars program to develop the OA-BIO project.

The Swiss AO Research Institute Davos (ARI) is part of the AO Foundation, which is the biggest trauma and orthopaedic network worldwide globally. In its work to advance the AO mission, ARI's purpose is to advance orthopaedic patient care through innovative research and development.

‍

Mauro Alini’s team from ARI, is part of our European Consortium with 4Moving Biotech, Chondrometrics and the Utrecht University which has been awarded funding through the highly competitive EUREKA-Eurostars program to develop the OA-BIO project.

Chondrometrics is a leading provider of medical image analysis services to researchers in academia and in the pharmaceutical industry. The focus of the company is on quantitative analysis of articular cartilage, meniscus, and muscle from magnetic resonance images (MRI), and on the research of osteoarthritis.

‍

Chondrometrics is part of our European Consortium with 4Moving Biotech, AO Research Institute of Davos and the Utrecht University which has been awarded funding through the highly competitive EUREKA-Eurostars program to develop the OA-BIO project.

The Arthritis foundation is the leading private initiative in France to fund research on RMS.Its missions are prevention, awareness, communication, and funding of medical research in the field of RMS. The Foundation supports all aspects of research.

‍

It makes a special effort to promote so-called "translational" research.This research aims to accelerate the transition from fundamental data to clinical proof. In this respect, the Arthritis Foundation proposes to help mixed teams of researchers and clinicians to promote innovative projects, both to develop new diagnostic tools and to discover new treatments for severe rheumatism. The clinical aspect of research, which is done in direct contact with patients and their families, is also supported by encouraging the development of epidemiological studies or innovative clinical trials.

SATT LUTECH is a private technology transfer company whose purpose is to facilitate the transfer of early-stage innovations with a real potential to improve life quality.

‍

Since 2015, SATT Lutech has been working in close collaboration with 4P-Pharma and Prof. Francis Berenbaum’s Sorbonne University-INSERM laboratory on 4P004 project, now developed by 4Moving Biotech.

‍

In April 2021, SATT Lutech has participated in a €2M investment agreement with 4P-Pharma, French Tech Seed and business angels to implement 4P004 phase 1 clinical trial on Osteoarthritis patients.

With 400 million euros and managed by Bpifrance, the French Tech Seed fund is intended to give leverage to private investment in technology companies under 3 years of age.

‍

Bpifrance finances companies - at every stage of their development - with credit, guarantees and equity. Bpifrance supports them in their innovation projects and internationally.

‍

In April 2021, the French Tech Seed fund has participated in a €2M investment agreement with 4P-Pharma, SATT Lutech and business angels to implement 4P004 phase 1 clinical trial on Osteoarthritis patients.

4P-Pharma is a French clinical-stage biotechnology company specialized in the sourcing and acceleration of early-stage therapeutic molecules addressing unmet medical needs. Since 2014, 4P-Pharma has pre-evaluated more than 300 molecules and carried out technological due diligence on more than 18 of them.

‍

4P-Pharma has now incorporated two in clinical-stage asset centric companies including 4P004 into 4Moving Biotech.